Filing Analysis
Inmune Bio, Inc. announced that it received a research and development cash rebate from Australia totaling approximately $4.2 million on July 30, 2026.
📋 Key Facts
- Received a research and development cash rebate from Australia.
- Rebate amount is approximately $4.2 million.
- The event occurred on July 30, 2026.
Inmune Bio entered into a warrant inducement offer to encourage holders of April 2024 warrants to exercise 50% of their holdings at a discounted price. This move aims to extend the maturity date of the remaining unexercised warrants from June 30, 2026, to December 31, 2027.
🚩 Red Flags
- Warrant inducement/downward price adjustment: Reducing the exercise price is a dilutive event for existing shareholders.
- Liquidity pressure: The company is offering significant discounts to secure immediate cash ($905,957), suggesting a need for near-term working capital.
- Maturity extension: Extending warrant maturity dates often indicates the company needs more time to reach milestones or improve its balance sheet before warrants expire/convert.
📋 Key Facts
- Company offered a reduced exercise price of $1.40 per share (down from $1.95) for 50% of the April 2024 Warrants.
- Holders agreed to exercise 647,112 warrants for cash.
- The company expects to receive an aggregate of $905,957 in cash from this exercise.
- Maturity date for the remaining 50% of the April 2024 Warrants is extended from June 30, 2026, to December 31, 2027.
- The underlying shares are covered by an existing effective registration statement (File No. 333-279036).
Inmune Bio, Inc. announced it has received official meeting minutes from a pre-Marketing Authorization Application (pre-MAA) Scientific Advice meeting with the UK MHRA regarding CORDStrom™ (Ebstrocel™) for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
📋 Key Facts
- Meeting held with the UK Medicines & Healthcare products Regulatory Agency (MHRA).
- Subject of meeting: pre-MAA Scientific Advice for CORDStrom™ (Ebstrocel™).
- Indication: Recessive Dystrophic Epidermolysis Bullosa (RDEB).
- Meeting minutes have been officially accepted by the MHRA.
Inmune Bio held its annual meeting of stockholders on June 16, 2026, where shareholders approved the Third Amended and Restated 2021 Stock Incentive Plan and the election of directors.
🚩 Red Flags
- The approval of an evergreen provision and the increase in the share pool can lead to significant equity dilution for existing shareholders over the 2027-2031 period.
📋 Key Facts
- The 2021 Stock Incentive Plan share pool was increased from 6,500,000 to 9,158,525 shares.
- An 'evergreen provision' was approved, allowing automatic annual increases from 2027 through 2031 by the lesser of 10% of outstanding shares or a smaller amount determined by the board.
- CBIZ CPAs P.C. was ratified as the independent auditor for the fiscal year ending December 31, 2026.
- Directors David Moss, J. Kelly Ganjei, Tim Schroeder, Scott Juda, and Marcia Allen were elected.
- As of April 20, 2026, there were 26,585,258 shares of common stock outstanding.
Inmune Bio, Inc. issued a press release on June 2, 2026, announcing exploratory chi-separation (χ-separation) MRI imaging analysis results from the MINDFuL Phase 2 clinical trial of XPro™ (XPro1595) for early Alzheimer's disease.
📋 Key Facts
- The filing reports results from the MINDFuL Phase 2 clinical trial.
- The trial focuses on XPro™ (XPro1595) for patients with early Alzheimer's disease, including mild cognitive impairment (MCI) and mild Alzheimer’s disease dementia.
- The specific data released pertains to exploratory chi-separation (χ-separation) MRI imaging analyses.
Inmune Bio announced that the U.S. FDA has granted Fast Track designation to its drug candidate XPro™ (pegipanermin) for the treatment of early Alzheimer's disease. This designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
📋 Key Facts
- On May 14, 2026, the FDA granted Fast Track designation to XPro™ (pegipanermin).
- XPro™ is described as a first-in-class selective soluble TNF inhibitor.
- The target indication for the Fast Track designation is early Alzheimer's disease (AD).
- The announcement was disclosed under Item 8.01 (Other Events) and included the press release as Exhibit 99.1.
INmune Bio Inc. entered into an amended and restated license agreement with Anthony Nolan to secure the long-term supply of umbilical cord tissue for its CORDStrom™ platform. The parent company is now a direct party to the agreement, assuming joint liability for payment obligations including a 2% royalty on net sales.
📋 Key Facts
- The agreement was signed on April 29, 2026, amending a previous 2017 agreement between the subsidiary IMB and Anthony Nolan.
- INmune Bio Inc. (the parent) is now a party to the agreement and jointly liable for royalty payments.
- The royalty is set at 2% of net sales of products, capped at an annual maximum of £5,000,000.
- Service fees for umbilical cord tissue are £400 plus VAT, with annual CPI-linked increases starting January 1, 2027.
- The agreement term extends to 10 years from the date of the first commercial sale.
- The company can terminate the agreement with 30 days' notice, while Anthony Nolan requires 6 months' notice.
Inmune Bio, Inc. has furnished an updated investor presentation slide deck to be used in upcoming presentations. The filing is a standard Regulation FD disclosure and does not report any material changes to the company's operations or financial status.
📋 Key Facts
- The company filed the 8-K on February 27, 2026.
- The filing includes Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains the new Investor Presentation.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
INmune Bio announced it will host a webinar on February 27, 2026, to discuss the registrational pathway for its drug candidate XPro1595 (XPro™) in the treatment of early Alzheimer’s disease.
📋 Key Facts
- The webinar is scheduled for February 27, 2026, at 9:30 a.m. ET.
- The presentation will focus on the registrational pathway for XPro1595.
- The target indication for the drug candidate is early Alzheimer’s disease.
- The announcement was made via a press release attached as Exhibit 99.1.
Inmune Bio, Inc. filed an 8-K under Item 8.01 (Other Events) to announce a webinar on its CORDStrom therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), scheduled for February 26, 2026. This is a routine informational filing with no material financial or corporate governance implications.
📋 Key Facts
- Company will host a webinar on CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET
- Filing signed by CEO David Moss on February 19, 2026
- Company is listed on NASDAQ under ticker INMB, common stock par value $0.001 per share
- Company is incorporated in Nevada with principal offices in Boca Raton, Florida
- Company is NOT classified as an emerging growth company
- Press release attached as Exhibit 99.1
Inmune Bio announced two significant regulatory milestones regarding its CORDStrom program: a pre-submission package filing with the UK's MHRA and receipt of meeting minutes from an FDA End-of-Phase 2 (Type B) meeting.
📋 Key Facts
- Submitted pre-submission package for CORDStrom to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on February 10, 2026.
- Received official minutes from an End-of-Phase 2 (Type B) meeting with the U.S. Food and Drug Administration (FDA) on February 12, 2026.
Inmune Bio, Inc. issued a shareholder letter via press release to provide updates regarding the company's prior and future operations. The filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information subject to Section 18 liability.
🚩 Red Flags
- Use of Item 7.01 (Regulation FD) often indicates a non-standard material update or response to market inquiries rather than a formal corporate action.
📋 Key Facts
- The company issued a shareholder letter on January 27, 2026.
- The disclosure includes updates on both historical and future operations.
- Information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Inmune Bio, Inc. entered into a Warrant Amendment on December 22, 2025, to modify the terms of existing warrants issued in April 2024. The amendment reduces the exercise price and extends the expiration date to June 30, 2026.
🚩 Red Flags
- Warrant price reduction (downward adjustment) often indicates a need to incentivize warrant holders or prevent expiration without exercise, potentially signaling downward pressure on share price.
- The modification of terms for existing securities can lead to dilution and may reflect difficulty in meeting previous capital raising targets.
📋 Key Facts
- Amendment affects an aggregate of 1,348,315 outstanding April 2024 Warrants.
- Exercise price reduced to $1.95 per share.
- Expiration date extended to June 30, 2026.
- Company received $0.05 per warrant in consideration, totaling $67,416 in aggregate proceeds.
- The new exercise price of $1.95 is noted as being greater than the Nasdaq Minimum Price requirement.
Inmune Bio, Inc. entered into an 'at-the-market' (ATM) sales agreement with A.G.P./Alliance Global Partners to facilitate the potential sale of up to $65 million in common stock.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $65 million ATM offering capacity.
- The use of an ATM facility often indicates a need for immediate liquidity to fund operations (common in biotech micro-caps).
📋 Key Facts
- Entered into a Sales Agreement with A.G.P./Alliance Global Partners on December 19, 2025.
- The agreement allows for the offering and sale of up to $65,000,000 of common stock.
- Sales will be conducted via an 'at-the-market' (ATM) offering method pursuant to Rule 415(a)(4).
- A.G.P. will receive a 3.0% commission on the aggregate gross proceeds from each sale.
- The offering is based on a previously effective S-3 shelf registration statement (File No. 279036) declared effective on August 7, 2024.
Inmune Bio, Inc. is terminating its $75 million At-The-Market (ATM) Sales Agreement with RBC Capital Markets and BTIG LLC, effective December 19, 2025. The company has already utilized a portion of the facility to raise approximately $10.5 million.
🚩 Red Flags
- Termination of a large ATM facility ($75M) may suggest the company no longer intends to dilute shareholders through this specific mechanism, but it could also indicate a shift in capital strategy or lack of need for further immediate equity financing.
📋 Key Facts
- Termination of Amended and Restated At-The-Market Sales Agreement with RBC Capital Markets, LLC and BTIG, LLC.
- Effective date of termination: December 19, 2025.
- Original aggregate offering size: up to $75,000,000.
- Shares issued under the agreement prior to termination: 1,353,469 shares.
- Net proceeds raised via the ATM program: approximately $10.5 million.
Inmune Bio, Inc. has entered into Amendment No. 5 to its Rights Agreement with VStock Transfer, LLC. The amendment extends the expiration of the existing rights agreement through December 31, 2026, with automatic one-year extensions.
📋 Key Facts
- Amendment No. 5 to the Rights Agreement was entered into on December 5, 2025.
- The amendment extends the expiration date of the Rights Agreement to December 31, 2026.
- The agreement includes an automatic extension provision for successive one-year terms unless rejected by the Board of Directors.
- VStock Transfer, LLC serves as the Rights Agent.
Inmune Bio issued two press releases regarding clinical trial data and platform technology. The filings announce neuroimaging data from the Phase 2 MINDFuL trial for XPro1595 in Alzheimer's patients and an overview of mesenchymal stromal cell therapy applications.
📋 Key Facts
- Announced new neuroimaging data from Phase 2 MINDFuL trial of XPro1595 (dated Dec 1, 2025).
- The clinical trial targets patients with early Alzheimer's disease and elevated neuroinflammation.
- Released an overview regarding future research applications for the CORDStrom™ mesenchymal stromal cell platform (dated Dec 5, 2025).
Inmune Bio, Inc. filed an 8-K to announce amendments to the employment agreements of its President/CEO and CFO. The amendments were made to correct mistakes in original agreements dated November 26, 2025.
🚩 Red Flags
- Administrative errors in executive compensation agreements filed only days prior (Nov 26 vs Dec 2) may suggest internal control weaknesses regarding payroll or legal review processes.
📋 Key Facts
- Amendment to David J. Moss's (President & CEO) agreement restates base salary to $454,000 per annum and option grant to 750,000 shares.
- Amendment to Cory Ellspermann's (CFO) agreement restates base salary to $240,000 per annum.
- The amendments were executed on December 2, 2025, to correct mistakes in agreements dated November 26, 2025.
INmune Bio, Inc. announced new employment agreements for its CEO (David J. Moss), CFO (Cory Ellspermann), and CSO (Mark Lowdell) effective November 1, 2025.
🚩 Red Flags
- Significant severance obligations (18 months of salary) for all three key executives in the event of involuntary termination.
📋 Key Facts
- CEO David J. Moss: $500,000 base salary + 50% target bonus; granted 800,000 stock options; 18-month severance package.
- CFO Cory Ellspermann: $275,000 base salary + 40% target bonus; granted 300,000 stock options; 18-month severance package.
- CSO Mark Lowdell: Agreement with INmune Bio International Limited (subsidiary); £300,000 base salary + up to 20% bonus; 18-month severance package.
- All agreements include 'Change of Control' acceleration clauses for unvested options.
Inmune Bio, Inc. announced that stockholders approved a one-time repricing of stock options for employees and directors at the November 18, 2025, special meeting. The repricing reduces the exercise price of up to 5,511,000 shares to $1.50 per share.
🚩 Red Flags
- Related-party transaction: The repricing directly benefits insiders (executives and directors).
- Potential signal of significant underwater options, suggesting past stock price performance has been poor.
- Dilution/revaluation risk: Repricing existing options can be viewed as a form of compensation that may not align with shareholder interests.
📋 Key Facts
- Stockholders approved a one-time option repricing on November 18, 2025.
- The repriced options cover up to an aggregate of 5,511,000 shares of common stock.
- The new exercise price is set at $1.50 per share (the closing price on the Repricing Date).
- Eligible optionholders include current employees, executive officers, and members of the Board of Directors.
- The repricing was previously approved by the Board on September 30, 2025.
Inmune Bio, Inc. has filed an 8-K to furnish an investor presentation under Item 7.01 (Regulation FD Disclosure). The filing does not contain material financial changes or structural corporate updates.
📋 Key Facts
- The company furnished a slide deck (Exhibit 99.1) for use in future presentations.
- The information is provided pursuant to Regulation FD and is not considered 'filed' for purposes of Section 18 liability.
- Report date: November 10, 2025.
Inmune Bio, Inc. announced its financial results for the quarter ended September 30, 2025, and provided a general business update via an 8-K filing.
📋 Key Facts
- Report date: October 30, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes results of operations and financial condition under Item 2.02
- A press release was issued as Exhibit 99.1
Inmune Bio, Inc. announced it will host a conference call on October 30, 2025, to discuss its third quarter results for the period ending September 30, 2025, and provide a corporate update.
📋 Key Facts
- Conference call scheduled for Thursday, October 30, 2025, at 4:30 p.m. ET.
- Purpose of call is to discuss Q3 2025 financial results (ended Sept 30, 2025).
- The company will also provide a general corporate update during the call.
Inmune Bio, Inc. announced that CEO David Moss will participate in a dermatologic rare disease panel at the upcoming Maxim Growth Summit scheduled for October 22–23, 2025.
📋 Key Facts
- CEO David Moss to participate in a Dermatologic Rare Disease Panel.
- Event: Maxim Growth Summit presented by Maxim Group LLC.
- Date of event: October 22–23, 2025.
- Location: Hard Rock Hotel, New York City.
Inmune Bio, Inc. announced the submission of a manuscript to 'npj Dementia' (a Nature Portfolio journal) detailing Phase 2 MINDFuL trial results for its drug XPro1595 in treating Early Alzheimer’s Disease with Inflammation (ADi). The filing serves as a formal announcement of clinical data being submitted for peer review.
📋 Key Facts
- Submission of manuscript titled 'XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial'.
- Target journal: npj Dementia (Nature Portfolio).
- Clinical trial phase: Phase 2 MINDFuL trial.
- Drug candidate: XPro1595 (Selective Soluble TNF Neutralizer).
Inmune Bio announced its Q2 2025 financial results and provided a clinical business update. Notably, the company reported that its Phase I/II 'CaRe PC' trial for INKmune™ in metastatic castration-resistant prostate cancer has met primary and secondary endpoints.
📋 Key Facts
- Company announced Q2 2025 financial results (quarter ended June 30, 2025).
- Phase I/II 'CaRe PC' trial of INKmune™ for metastatic castration-resistant prostate cancer met primary and secondary endpoints.
- The CaRe PC trial is now closed to further enrollment.
Inmune Bio, Inc. issued an 8-K to announce the upcoming release of video findings from its Phase 2 MINDFuL trial regarding XPro™. The company also updated its corporate presentation to include more clinical program data.
📋 Key Facts
- Announced publication of a video detailing additional findings from the Phase 2 MINDFuL trial for XPro™ on their YouTube channel.
- The video release is scheduled to follow the Alzheimer’s Association International Conference in Toronto, Canada.
- Released an updated corporate presentation containing information on clinical programs and company operations.
Inmune Bio announced that it will present additional analyses from its Phase 2 MINDFuL trial for XPro™ at the Alzheimer’s Association International Conference on July 29, 2025. The presentation focuses on data regarding the selective soluble tumor necrosis factor inhibitor.
📋 Key Facts
- Trial Name: Phase 2 MINDFuL trial
- Drug Candidate: XPro™ (selective soluble tumor necrosis factor inhibitor)
- Event: Alzheimer’s Association International Conference
- Presentation Date: Tuesday, July 29, 2025, between 2:00 and 3:30 PM ET
- Location: Toronto, Canada
Inmune Bio, Inc. completed a registered direct offering of 3,000,000 shares at $6.30 per share, raising approximately $18.9 million in gross proceeds. The offering was conducted via two healthcare-focused institutional investors and closed on June 30, 2025.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of 3 million new shares.
📋 Key Facts
- Total shares offered: 3,000,000 common stock shares.
- Offering price: $6.30 per share (at-the-market).
- Aggregate gross proceeds: Approximately $18.9 million before fees and expenses.
- Placement Agent: A.G.P./Alliance Global Partners (7.0% cash fee plus expense reimbursement).
- Offering Type: Registered direct offering under an existing S-3 shelf registration.
- Closing Date: June 30, 2025.
Inmune Bio, Inc. announced topline results from its Phase 2 MINDFuL clinical trial evaluating XPro™ for patients with early Alzheimer’s disease. The company also released an updated corporate presentation to provide further context on its clinical programs.
📋 Key Facts
- Announced topline results from the Phase 2 MINDFuL trial (June 30, 2025).
- The trial evaluates XPro™ in patients with early Alzheimer’s disease.
- Released an updated corporate presentation detailing clinical programs.
Inmune Bio announced it will host a conference call on June 30, 2025, to present top-line data from its Phase 2 MINDFuL clinical trial for early Alzheimer’s disease. This is a high-impact clinical milestone event common in biotech micro-caps.
📋 Key Facts
- Conference call scheduled for Monday, June 30, 2025, at 8:00 a.m. ET.
- Data to be presented pertains to the Phase 2 MINDFuL trial.
- The clinical focus is on early Alzheimer’s disease.
Inmune Bio held its annual meeting of stockholders on June 10, 2025, where shareholders approved the election of directors and several key proposals. Notably, stockholders approved an increase in shares available under the 2021 Stock Incentive Plan and ratified CBIZ CPAs P.C. as independent auditors.
🚩 Red Flags
- Increase in share pool for stock incentive plan (potential dilution).
📋 Key Facts
- Stockholders approved the Second Amended and Restated 2021 Stock Incentive Plan, increasing share capacity from 4,000,000 to 6,500,000 shares.
- The amended incentive plan now permits acceleration of vesting awards upon a change of control.
- Five directors were elected: Raymond J. Tesi, MD; J. Kelly Ganjei; Tim Schroeder; Scott Juda, JD; and Marcia Allen.
- CBIZ CPAs P.C. was ratified as independent auditors for the fiscal year ending December 31, 2025.
- Stockholders approved a non-binding advisory vote on executive compensation frequency to occur every three years.
- The company announced a new collaboration with Dr. Kirsty Dixon (Virginia Commonwealth University) regarding traumatic brain injury and Alzheimer's disease.
Inmune Bio, Inc. announced its participation in the upcoming 2025 RBC Capital Markets Global Healthcare Conference scheduled for May 20-21, 2025.
📋 Key Facts
- The Company will present at the 2025 RBC Capital Markets Global Healthcare Conference.
- Conference dates: May 20-21, 2025.
- Location: InterContinental New York Barclay.
Inmune Bio, Inc. announced its financial results for the fiscal quarter ended March 31, 2025, and provided a general business update via an 8-K filing.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 8, 2025
- The filing includes results of operations and financial condition updates under Item 2.02.
Inmune Bio, Inc. has dismissed its independent auditor, Marcum LLP, following the acquisition of Marcum's attest business by CBIZ CPAs P.C. The company has engaged CBIZ CPAs as its new auditor for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Going concern language: Previous audit reports contained an explanatory paragraph relating to substantial doubt about the company's ability to continue as a going concern.
- Auditor change combined with existing going concern uncertainty (Red Flag Escalator).
📋 Key Facts
- Dismissal of Marcum LLP effective May 7, 2025.
- Engagement of CBIZ CPAs P.C. as the new independent registered public accounting firm for FY 2025.
- The dismissal is a result of CBIZ CPAs acquiring the attest business of Marcum LLP on November 1, 2024.
- Marcum's audit reports for fiscal years ended December 31, 2024, and 2023 included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
Inmune Bio, Inc. announced a scheduled conference call for May 8, 2025, to discuss its Q1 2025 financial results and provide a corporate update.
📋 Key Facts
- Conference call scheduled for Thursday, May 8, 2025, at 4:30 p.m. ET.
- Purpose of call is to discuss Q1 results ended March 31, 2025.
- The company will also provide a general corporate update during the call.
Inmune Bio, Inc. announced that it received a favorable patentability opinion from the USPTO regarding its international patent application for therapeutic compositions comprising human umbilical cord-derived mesenchymal stromal cells.
📋 Key Facts
- Received a favorable patentability opinion from the USPTO acting as International Search Authority.
- The opinion covers all claims in international patent application PCT/US25/17028.
- Patent title: 'THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS'.
- Disclosure made under Item 7.01 (Regulation FD Disclosure).
Inmune Bio, Inc. announced a strategic partnership with the Cell and Gene Therapy Catapult to establish large-scale, commercial-ready manufacturing capabilities for its cell therapy platforms.
📋 Key Facts
- Partnership established with Cell and Gene Therapy Catapult.
- Objective is to create large-scale, commercial-ready manufacturing for cell therapy platforms.
- Announcement date: April 14, 2025.
Inmune Bio, Inc. presented a poster at the International Conference on Alzheimer’s and Parkinson’s Diseases regarding patient demographics and biomarker status in its MINDFul Phase II trial for early Alzheimer's disease.
📋 Key Facts
- Presented a poster presentation at the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders in Vienna, Austria.
- The presentation focused on demographics and biomarker status of patients enrolled in the MINDFul Phase II blinded, randomized trial.
- The trial targets patients with early Alzheimer's disease and biomarkers of inflammation.
- Information was disclosed under Item 7.01 (Regulation FD Disclosure) and is considered furnished, not filed.
Inmune Bio, Inc. announced it will present a scientific poster at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders in Vienna, Austria.
📋 Key Facts
- Event: Presentation of a poster at the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders.
- Location: Vienna, Austria.
- Date of Event: April 1-5, 2025.
- Reporting Date: April 1, 2025.
Inmune Bio, Inc. announced its financial results for the fiscal year ended December 31, 2024, and provided a general business update via an Item 2.02 filing.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and business updates.
- The information in Item 2.02 is furnished rather than filed for purposes of Section 18 liability.
Inmune Bio, Inc. announced it will host a conference call on March 27, 2025, to discuss its fourth quarter 2024 financial results and provide a corporate update.
📋 Key Facts
- Conference call scheduled for Thursday, March 27, 2025, at 4:30 p.m. ET.
- The call will cover Q4 ended December 31, 2024 results.
- The company intends to provide a general corporate update during the call.
Inmune Bio, Inc. has filed an 8-K to furnish an investor presentation under Regulation FD. This is a routine disclosure used to provide supplemental information to the public simultaneously with private communications.
📋 Key Facts
- The company furnished an Investor Presentation as Exhibit 99.1.
- The filing was made on March 4, 2025.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Inmune Bio, Inc. announced the completion of the third and highest dose cohort in its Phase I trial for INKmune™ (natural killer cell therapy) targeting metastatic castration-resistant prostate cancer. This milestone allows the company to proceed with opening the Phase II high dose cohort.
📋 Key Facts
- Completed the third and highest dose cohort of the Phase I portion of the INKmune™ trial.
- The clinical trial targets men with metastatic castration-resistant prostate cancer.
- Successful completion of this cohort enables the opening of the Phase II high dose cohort.
Inmune Bio entered into a license agreement with Great Ormond Street Hospital (GOSH) for the exclusive commercial use of clinical trial data from the Mission EB study regarding CORDStrom. Additionally, the company successfully terminated an existing loan agreement with Silicon Valley Bank.
🚩 Red Flags
- The company has obligations to sponsor the supply of CORDStrom to UK patients in an open-label continuation study, representing ongoing clinical/supply costs.
📋 Key Facts
- Entered License Agreement with GOSH on February 6, 2025, for exclusive commercial use of Mission EB study data.
- Upfront payment to GOSH: £250,000 (~$0.3 million) due within 30 days.
- Milestone payment: Up to £6,000,000 (~$7.5 million) upon first marketing authorization from FDA, EMA, or MHRA.
- The agreement covers applications for CORDStrom treatment of pediatric RDEB in the US, EU, and UK.
- Term of License Agreement is 10 years.
- Terminated a Loan and Security Agreement with Silicon Valley Bank (SVB) as of February 6, 2025.
- No amounts were due or owed to SVB at the time of termination; no early termination penalty was paid.
Inmune Bio, Inc. has filed an 8-K to furnish updated investor and webinar presentation materials via its website. This filing is a routine disclosure of promotional/informational materials under Regulation FD.
📋 Key Facts
- Company prepared an 'Investor Presentation' (Exhibit 99.1) for use in various presentations.
- Company prepared a 'Webinar Presentation' (Exhibit 99.2) for webinar use.
- Materials are available on the company's investor relations website.
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Inmune Bio, Inc. announced the commencement of patient treatment in its Phase I/II clinical trial for metastatic castration-resistant prostate cancer at West Los Angeles Veterans Administration Hospital.
📋 Key Facts
- First patient treated in Phase I/II trial for men with metastatic castration-resistant prostate cancer.
- Trial site: West Los Angeles Veterans Administration Hospital.
- Announcement date: January 28, 2025.
Inmune Bio, Inc. has extended its Rights Agreement with VStock Transfer, LLC through December 30, 2025. Additionally, the company's Compensation Committee approved several stock option grants for non-employee directors and key executives.
🚩 Red Flags
- The continuous extensions of the Rights Agreement (Amendments 1 through 4) suggest an ongoing need to manage shareholder rights or potential dilution mechanisms over a multi-year period.
📋 Key Facts
- Amendment No. 4 to the Rights Agreement extends the expiration date of the Rights Agreement to December 30, 2025.
- Non-employee directors (Timothy Schroeder, J. Kelly Ganjei, Scott Juda, and Marcia Allen) were granted options for 32,500 shares each at an exercise price of $5.05.
- CEO Ramond J. Tesi was granted options to purchase 226,000 shares at $5.05 per share.
- CFO David Moss was granted options to purchase 223,000 shares at $5.05 per share.
- CSO Mark Lowdell was granted options to purchase 140,000 shares at $5.05 per share.
- All option grants are set to vest on December 5, 2026 (two-year cliff) and expire on December 4, 2034.
Inmune Bio, Inc. announced the completion of patient randomization for its global, blinded, randomized Phase 2 clinical trial targeting patients with Early Alzheimer's Disease (AD) and biomarkers of elevated neuroinflammation.
📋 Key Facts
- Completed randomization of patients on November 11, 2024.
- Trial focus: Global, blinded, randomized Phase 2 study for Early AD with biomarkers of elevated neuroinflammation.
- The announcement was made via press release on November 13, 2024.
Inmune Bio, Inc. has filed an 8-K to furnish an updated Investor Presentation via Item 7.01 (Regulation FD Disclosure). The filing serves as a mechanism to make corporate presentation materials available to all investors simultaneously.
📋 Key Facts
- The company released an 'Investor Presentation' to be used in future presentations.
- The presentation is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
- The document is available on the company's website under the Investor Relations section.
Inmune Bio, Inc. filed an 8-K to furnish its quarterly financial results and business update for the period ended September 30, 2024.
📋 Key Facts
- Report date: October 31, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business updates.
- Company is an emerging growth company.
Inmune Bio, Inc. issued an 8-K to announce an upcoming webinar scheduled for November 7, 2024, regarding the use of EMACC as a measurement tool in early Alzheimer’s clinical trials.
📋 Key Facts
- The company is hosting a webinar titled 'Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials'.
- The webinar is scheduled to take place on November 7, 2024.
- The filing serves as a formal announcement of an upcoming corporate event/press release.
Inmune Bio, Inc. issued an 8-K to announce the publication of a research paper in the journal Cell Reports regarding its XPro1595 candidate.
📋 Key Facts
- Publication date: October 24, 2024
- Journal: Cell Reports
- Scientific finding: XPro1595 promotes remyelination in an animal model of demyelinating disease.
- The filing serves to incorporate a press release (Exhibit 99.1) by reference.
Inmune Bio, Inc. announced it will host a conference call on October 31, 2024, to discuss its third quarter financial results for the period ended September 30, 2024, and provide a corporate update.
📋 Key Facts
- Conference call scheduled for Thursday, October 31, 2024, at 4:30pm EDT.
- Purpose of call is to discuss Q3 2024 results (ended Sept 30, 2024) and provide a corporate update.
- The filing includes a press release as Exhibit 99.1.
Inmune Bio, Inc. filed an 8-K to announce management's participation in the upcoming Maxim Healthcare Virtual Summit scheduled for October 15-17, 2024.
📋 Key Facts
- Management will participate in the Maxim Healthcare Virtual Summit from October 15-17, 2024.
- The filing serves as a formal announcement of upcoming investor relations activity.
Inmune Bio announced clinical progress regarding its natural killer cell therapy, INKmune. The company reported initial results from the first patient cohort in a Phase I/II trial targeting men with metastatic castration-resistant prostate cancer.
📋 Key Facts
- Company is advancing INKmune in a Phase I/II clinical trial.
- Target indication: Men with metastatic castration-resistant prostate cancer.
- Announced initial results from the first patient cohort on September 26, 2024.
Inmune Bio announced positive results from additional analysis of blinded data in its AD02 Phase II Alzheimer’s Disease trial. The analysis showed exceptional performance of a novel cognitive measure (EMACC) and a significant correlation with the standard clinical dementia rating sum of boxes.
📋 Key Facts
- Company reported on Phase II Alzheimer's Disease (AD) trial results for AD02.
- Analysis focused on blinded data regarding the EMACC cognitive measure.
- Results demonstrated 'exceptional performance' of the EMACC measure.
- Found a highly significant correlation between EMACC and the clinical dementia rating sum of boxes (the accepted endpoint).
Inmune Bio, Inc. entered into securities purchase agreements for a registered direct offering of 2,341,260 shares and warrants, totaling approximately $13 million in gross proceeds. The offering includes participation from both external investors and company insiders.
🚩 Red Flags
- Related-party transaction: Insiders are participating in the offering at a higher price ($6.50) than external investors ($5.50).
- Potential dilution: Issuance of over 2.3 million new shares and warrants will dilute existing shareholders.
📋 Key Facts
- Aggregate gross proceeds: approximately $13,000,000 before fees.
- Total securities: 2,341,260 shares of common stock and an equal number of warrants.
- Investor pricing: $5.50 per share plus related warrant; Insider pricing: $6.50 per share plus related warrant.
- Warrant exercise price: $6.40 per share.
- Warrants are exercisable on or after March 16, 2025.
- Placement agent (A.G.P/Alliance Global Partners) to receive a 7.0% fee from investor proceeds and 3.5% from insider proceeds.
- Offering expected to close around September 16, 2024.
Inmune Bio, Inc. announced its intention to present at the upcoming Baird 2024 Global Healthcare Conference scheduled for September 10-11, 2024.
📋 Key Facts
- The company will participate in the Baird 2024 Global Healthcare Conference.
- Conference dates are September 10-11, 2024.
- Announcement made via press release on September 3, 2024.
Inmune Bio, Inc. has entered into an Amended and Restated At-The-Market (ATM) Sales Agreement to facilitate the sale of common stock up to a total aggregate price of $75,000,000. The offering will be conducted through RBC Capital Markets, LLC and BTIG, LLC.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $75M ATM program.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing operational burn rates.
📋 Key Facts
- Entered into an Amended and Restated At-The-Market Sales Agreement on August 9, 2024.
- Aggregate offering price of up to $75,000,000 in common stock.
- Sales agents are RBC Capital Markets, LLC and BTIG, LLC.
- Commission for sales agents is set at 3.0% of gross sales proceeds.
- The offering will be conducted under a Form S-3 registration statement declared effective on August 7, 2024.
Inmune Bio, Inc. filed an 8-K to furnish its quarterly financial results and business update for the period ended June 30, 2024.
📋 Key Facts
- The filing relates to the quarter ended June 30, 2024.
- Report date of earliest event: August 1, 2024.
- The company is an emerging growth company.
- Financial results and business update were issued via press release (Exhibit 99.1).
Inmune Bio, Inc. announced it will host a conference call on August 1, 2024, to discuss its second quarter 2024 financial results and provide a corporate update.
📋 Key Facts
- Conference call scheduled for Thursday, August 1, 2024, at 4:30 p.m. ET.
- The call will focus on results for the quarter ended June 30, 2024.
- A corporate update will be provided during the call.
Inmune Bio, Inc. held its annual meeting of stockholders on July 19, 2024. The results included the election of five directors and the ratification of Marcum LLP as the company's independent auditors for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Resignation of a director nominee (Edgardo Baracchini) prior to vote finalization.
📋 Key Facts
- Annual meeting held on July 19, 2024.
- Five directors elected: Raymond J. Tesi, MD; J. Kelly Ganjei; Tim Schroeder; Scott Juda, JD; and Marcia Allen.
- Edgardo Baracchini resigned from the board prior to the vote being finalized.
- Stockholders ratified Marcum LLP as independent auditors for fiscal year 2024 with 14,504,668 votes in favor.
Inmune Bio, Inc. announced the immediate resignation of Edgardo Baracchini from its Board of Directors on July 5, 2024. Mr. Baracchini served as Chairman of the Compensation Committee and was a member of the Nominating and Corporate Governance Committee.
🚩 Red Flags
- None identified; the filing contains standard 'no disagreement' language which typically mitigates concerns regarding sudden departures.
📋 Key Facts
- Edgardo Baracchini resigned from the Board of Directors effective July 5, 2024.
- Mr. Baracchini had served on the Board since August 2019.
- He held roles as Chairman of the Compensation Committee and member of the Nominating and Corporate Governance Committee.
- The company explicitly stated that his resignation was not due to any disagreement regarding policies, operations, or practices.
Inmune Bio announced that its Phase II Alzheimer's disease clinical trial (AD02) has undergone a blinded sample size re-estimation. The company confirmed the trial is now appropriately powered to meet its primary endpoint.
📋 Key Facts
- Trial Name: AD02 (Phase II Alzheimer’s disease clinical trial).
- Primary Endpoint: Early Mild Alzheimer’s Cognitive Composite.
- Event Date: June 27, 2024.
- Methodology: Blinded sample size re-estimation was performed to ensure the trial is appropriately powered.
Inmune Bio, Inc. announced the board's approval of a new stock option grant for CEO Ramond J. Tesi on June 10, 2024.
🚩 Red Flags
- Immediate vesting of stock options can sometimes be viewed as a lack of long-term incentive alignment, though common in some micro-cap structures.
📋 Key Facts
- Grant Date: June 10, 2024
- Recipient: Ramond J. Tesi (CEO)
- Number of Shares: 37,882 shares of common stock
- Exercise Price: $8.72 per share
- Vesting: Immediately vested and exercisable upon grant date
- Expiration Date: June 9, 2034
- Plan: 2021 Stock Incentive Plan
Inmune Bio announced it will be added to the Russell 3000 Index as part of the annual reconstitution, effective July 1, 2024. This inclusion is a significant milestone for index tracking and potential passive fund inflows.
📋 Key Facts
- Company to join the broad-market Russell 3000® Index.
- Effective date: Open of US equity markets on July 1, 2024.
- Event triggered by the 2024 Russell US Indexes annual reconstitution.
Inmune Bio, Inc. announced an amendment to its bylaws on May 22, 2024, changing the voting standard for director elections from plurality to a majority voting standard.
📋 Key Facts
- Board of Directors approved the amendment on May 22, 2024.
- Voting standard for election of directors changed from plurality to majority.
- The Amendment became effective immediately on May 22, 2024.
Inmune Bio, Inc. announced the approval of various stock option grants for non-employee directors and key executive officers on May 14, 2024.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Non-employee directors granted options to purchase 12,500 shares each at an exercise price of $9.92.
- CEO Ramond J. Tesi granted options for 160,000 shares at $9.92 per share; vesting over 4 years (25% after 1 year, then monthly).
- CFO David Moss granted options for 160,000 shares at $9.92 per share; vesting over 4 years.
- CSO Mark Lowdell granted options for 100,000 shares at $9.92 per share; vesting over 4 years.
- All executive options expire on May 13, 2034.
Inmune Bio, Inc. filed an 8-K to announce the release of its first quarter 2024 financial results and a corporate update. The filing serves as a formal notice for upcoming earnings calls and subsequent press releases regarding quarterly performance.
📋 Key Facts
- Company announced Q1 2024 financial results ended March 31, 2024.
- A conference call was scheduled for May 9, 2024, at 4:30 PM ET to discuss the results and provide a corporate update.
- The filing includes press releases dated May 7, 2024 (Exhibit 99.1) and May 9, 2024 (Exhibit 99.2).
Inmune Bio announced clinical progress regarding its INKmune™ NK cell therapy for prostate cancer and provided a long-term follow-up update on XPro™ treatment for Alzheimer's Disease. The filing consists of two press releases detailing trial cohort progression and compassionate use data.
📋 Key Facts
- Completed the first cohort of the Phase 1/2 study of INKmune™ Natural Killer cell therapy in metastatic castration-resistant prostate cancer patients (April 29, 2024).
- Initiated the second cohort of the same INKmune™ clinical study.
- Reported long-term follow-up data for two patients receiving XPro™ via an Australian compassionate use program (Special Access Scheme) for over three years (April 30, 2024).
- The Alzheimer's update pertains to a Phase 1b trial completed in 2021.
Inmune Bio, Inc. entered into a securities purchase agreement for a registered direct offering of 986,000 shares and warrants at $9.84 per unit, raising approximately $9.7 million in gross proceeds.
🚩 Red Flags
- Warrant termination clause is tied to positive clinical data (Phase 2 Alzheimer's), which can lead to rapid dilution if the company hits its milestones.
- The offering is a registered direct offering, often used by micro-cap biotech firms to bridge cash runway needs.
📋 Key Facts
- Offering size: 986,000 shares of common stock and 986,000 warrants to purchase common stock.
- Price per unit (Share + Warrant): $9.84.
- Aggregate gross proceeds: Approximately $9,702,240 before fees.
- Warrant exercise price: $9.84.
- Warrant termination trigger: 2 years from initial exercise or 30 trading days after reporting positive top-line Phase 2 Alzheimer’s data for XPro1595 (p-value ≤ 0.05).
- Placement Agent: Maxim Group LLC, receiving a 6.0% cash fee.
- Expected closing date: On or about April 29, 2024.
Inmune Bio announced the completion of extended stability validation for its XPro™ product in solution at 2-8C. Additionally, the company has filed a patent application following the development of a new anti-drug antibody assay to mitigate false positive readings.
📋 Key Facts
- Completed extended stability validation for XPro™ continuous storage in solution at 2-8°C on April 23, 2024.
- Successfully developed an anti-drug antibody assay for XPro™ that mitigates false positive readings from conventional bridging and affinity capture elution (ACE) formats.
- Filed a patent application related to the new assay development.
Inmune Bio, Inc. entered into a securities purchase agreement for a registered direct offering of 571,592 shares and warrants at $8.32 per unit, raising approximately $4.77 million in gross proceeds.
🚩 Red Flags
- Insider participation: Certain members of management, board of directors, and key employees participated in the offering at a combined price of $8.445 per unit.
- Dilution: Issuance of warrants linked to clinical data milestones (XPro1595 Phase 2) can lead to significant dilution upon news-driven volatility.
📋 Key Facts
- Registered direct offering of 571,592 shares of common stock and 571,592 warrants.
- Offering price: $8.32 per share and warrant unit.
- Aggregate gross proceeds: approximately $4,771,289 (before fees).
- Warrant exercise price: $9.152 (10% premium to offering price).
- Warrants expire 2 years from exercise or 30 trading days after top-line data reporting for the Phase 2 Alzheimer’s program of XPro1595.
- Placement agent fee: 4% of gross proceeds paid to LifeSci Capital LLC.
- Expected closing date: on or about April 24, 2024.
Inmune Bio, Inc. issued an 8-K to announce the presentation of clinical data regarding INB03, a TNF inhibitor, for the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC). The filing serves as a formal notification of the press release containing these scientific updates.
📋 Key Facts
- Company presented data on INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF).
- The clinical focus is on high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).
- Data presentation occurred on April 8, 2024.
- The filing includes a press release as Exhibit 99.1.
Inmune Bio, Inc. issued an 8-K to announce its full-year financial results for the period ended December 31, 2023, and provided a general business update via press release.
📋 Key Facts
- Reporting date of event: March 28, 2024
- Filing covers fiscal year ended December 31, 2023
- The filing includes an announcement of financial results and a business update via Exhibit 99.1
- Company is an emerging growth company
Inmune Bio, Inc. filed an 8-K to announce a scheduled conference call for March 28, 2024. The purpose of the call is to discuss fourth quarter 2023 financial results and provide a corporate update.
📋 Key Facts
- Conference call scheduled for Thursday, March 28, 2024, at 4:30 PM ET.
- The call will cover Q4 results ended December 31, 2023.
- The company intends to provide a general corporate update during the call.
Inmune Bio announced that the FDA has lifted the full clinical hold on its Alzheimer’s disease clinical trial program. The company expects to complete Phase II patient enrollment by mid-2024, with top-line data expected roughly six months thereafter.
📋 Key Facts
- FDA has lifted the full clinical hold on the Company's Alzheimer's disease clinical trial program.
- Phase II trial patient enrollment is anticipated to be complete in mid-2024.
- Top-line data for the Phase II trial is expected approximately six months after the last patient is enrolled.
Inmune Bio announced the first patient dosing in its INKmune™ Phase I/II clinical trial for metastatic castration-resistant prostate cancer on December 27, 2023.
📋 Key Facts
- First patient dosed in men with metastatic castration-resistant prostate cancer occurred on December 27, 2023.
- The study is part of the INKmune™ Phase I/II clinical trial program.
- Announcement made via press release dated January 2, 2024.